Cargando…
The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
SIMPLE SUMMARY: Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative dec...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818833/ https://www.ncbi.nlm.nih.gov/pubmed/36612263 http://dx.doi.org/10.3390/cancers15010267 |
_version_ | 1784865082905198592 |
---|---|
author | Ferrés, Abel Reyes, Luís Di Somma, Alberto Topczewski, Thomaz Mosteiro, Alejandra Guizzardi, Giulia De Rosa, Andrea Halperin, Irene Hanzu, Felicia Mora, Mireia Alobid, Isam Aldecoa, Iban Bargalló, Núria Enseñat, Joaquim |
author_facet | Ferrés, Abel Reyes, Luís Di Somma, Alberto Topczewski, Thomaz Mosteiro, Alejandra Guizzardi, Giulia De Rosa, Andrea Halperin, Irene Hanzu, Felicia Mora, Mireia Alobid, Isam Aldecoa, Iban Bargalló, Núria Enseñat, Joaquim |
author_sort | Ferrés, Abel |
collection | PubMed |
description | SIMPLE SUMMARY: Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp’s grade IV, MRI T2-weighted tumor hyperintensity, and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET. ABSTRACT: Postoperative deserved outcomes in acromegalic patients are to normalize serum insulin-like growth factor (IGF-1), reduce the tumoral mass effect, improve systemic comorbidities, and reverse metabolic alterations. Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. From 2006 to 2019, 394 patients affected by PitNET were intervened via endoscopic endonasal transsphenoidal approach by the same senior surgeon. A total of 44 patients that met the criteria to be diagnosed as acromegalic and were followed up at least for 24 months (median of 66 months (26–156) were included in the present study. Multiple predictive variables [age, gender, preoperative GH and IGF-1 levels, maximal tumor diameter, Hardy’s and Knosp’s grade, MRI. T2-weighted tumor intensity, cytokeratin expression pattern, and clinicopathological classification] were evaluated through uni- and multivariate statistical analysis. Sparse probability of long-term remission was related to younger age, higher preoperative GH and- or IGF-1, group 2b of the clinicopathological classification, and sparsely granulated cytokeratin expression pattern. Augmented recurrence risk was related to elevated preoperative GH levels, tumor MRI T2-weighted hyperintensity, and sparsely granulated cytokeratin expression pattern. Finally, elevated risk for reintervention was related to group 2b of the clinicopathological classification, Knosp’s grade IV, and tumor MRI T2-weighted hyperintensity. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp’s grade IV, MRI T2-weighted tumor hyperintensity and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET. |
format | Online Article Text |
id | pubmed-9818833 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98188332023-01-07 The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up Ferrés, Abel Reyes, Luís Di Somma, Alberto Topczewski, Thomaz Mosteiro, Alejandra Guizzardi, Giulia De Rosa, Andrea Halperin, Irene Hanzu, Felicia Mora, Mireia Alobid, Isam Aldecoa, Iban Bargalló, Núria Enseñat, Joaquim Cancers (Basel) Article SIMPLE SUMMARY: Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp’s grade IV, MRI T2-weighted tumor hyperintensity, and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET. ABSTRACT: Postoperative deserved outcomes in acromegalic patients are to normalize serum insulin-like growth factor (IGF-1), reduce the tumoral mass effect, improve systemic comorbidities, and reverse metabolic alterations. Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. From 2006 to 2019, 394 patients affected by PitNET were intervened via endoscopic endonasal transsphenoidal approach by the same senior surgeon. A total of 44 patients that met the criteria to be diagnosed as acromegalic and were followed up at least for 24 months (median of 66 months (26–156) were included in the present study. Multiple predictive variables [age, gender, preoperative GH and IGF-1 levels, maximal tumor diameter, Hardy’s and Knosp’s grade, MRI. T2-weighted tumor intensity, cytokeratin expression pattern, and clinicopathological classification] were evaluated through uni- and multivariate statistical analysis. Sparse probability of long-term remission was related to younger age, higher preoperative GH and- or IGF-1, group 2b of the clinicopathological classification, and sparsely granulated cytokeratin expression pattern. Augmented recurrence risk was related to elevated preoperative GH levels, tumor MRI T2-weighted hyperintensity, and sparsely granulated cytokeratin expression pattern. Finally, elevated risk for reintervention was related to group 2b of the clinicopathological classification, Knosp’s grade IV, and tumor MRI T2-weighted hyperintensity. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp’s grade IV, MRI T2-weighted tumor hyperintensity and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET. MDPI 2022-12-30 /pmc/articles/PMC9818833/ /pubmed/36612263 http://dx.doi.org/10.3390/cancers15010267 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ferrés, Abel Reyes, Luís Di Somma, Alberto Topczewski, Thomaz Mosteiro, Alejandra Guizzardi, Giulia De Rosa, Andrea Halperin, Irene Hanzu, Felicia Mora, Mireia Alobid, Isam Aldecoa, Iban Bargalló, Núria Enseñat, Joaquim The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up |
title | The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up |
title_full | The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up |
title_fullStr | The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up |
title_full_unstemmed | The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up |
title_short | The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up |
title_sort | prognostic-based approach in growth hormone-secreting pituitary neuroendocrine tumors (pitnet): tertiary reference center, single senior surgeon, and long-term follow-up |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818833/ https://www.ncbi.nlm.nih.gov/pubmed/36612263 http://dx.doi.org/10.3390/cancers15010267 |
work_keys_str_mv | AT ferresabel theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT reyesluis theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT disommaalberto theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT topczewskithomaz theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT mosteiroalejandra theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT guizzardigiulia theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT derosaandrea theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT halperinirene theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT hanzufelicia theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT moramireia theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT alobidisam theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT aldecoaiban theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT bargallonuria theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT ensenatjoaquim theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT ferresabel prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT reyesluis prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT disommaalberto prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT topczewskithomaz prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT mosteiroalejandra prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT guizzardigiulia prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT derosaandrea prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT halperinirene prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT hanzufelicia prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT moramireia prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT alobidisam prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT aldecoaiban prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT bargallonuria prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup AT ensenatjoaquim prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup |